Expand TVTX Menu
TVTX MENU

TVTX Latest Press Releases

-- February 19, 2026 --

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:01 PM

-- February 12, 2026 --

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:30 PM

-- February 11, 2026 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- February 4, 2026 --

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit Business Wire 4:30 PM

-- January 30, 2026 --

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Encourages Investors and Potential Witnesses to Contact Law Firm Globe Newswire 8:50 PM

-- January 28, 2026 --

TVTX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm PRNewswire 7:10 AM

-- January 27, 2026 --

TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses Globe Newswire 7:54 AM

-- January 16, 2026 --

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm Business Wire 6:00 AM

-- January 14, 2026 --

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC Globe Newswire 4:04 PM

-- January 13, 2026 --

TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm Globe Newswire 6:58 PM
SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm Globe Newswire 3:05 PM
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS Business Wire 1:24 PM

-- January 12, 2026 --

Travere Therapeutics Provides Corporate Update and 2026 Outlook Business Wire 5:00 PM

-- January 5, 2026 --

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:30 PM

-- December 11, 2025 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- November 10, 2025 --

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:00 PM

-- November 6, 2025 --

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 Business Wire 11:00 AM

-- November 4, 2025 --

Travere Therapeutics to Participate at Upcoming Investor Conferences Business Wire 5:23 PM

-- October 30, 2025 --

Travere Therapeutics Reports Third Quarter 2025 Financial Results Business Wire 4:01 PM
Market Data Delayed 15 Minutes